The numbers coming out of retatrutide's clinical program are unlike anything seen before in obesity medicine. According to a report on the TRIUMPH-4 Phase 3 results, participants lost an average of nearly 56 pounds after 80 weeks on retatrutide — a figure that has prompted Eli Lilly, the maker of Mounjaro and Zepbound, to announce plans to file for FDA approval based on these study results. That single headline has reshaped the conversation around what pharmacological weight loss can realistically achieve.
Retatrutide — commonly referred to as reta in patient communities — is a once-weekly injectable medication developed by Eli Lilly. It works as a triple hormone receptor agonist, simultaneously activating three receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This triple-receptor mechanism, sometimes called "triple G" in patient community discussions, is what distinguishes retatrutide from earlier generation agents and helps explain its outsized efficacy on body weight.
The most rigorous efficacy snapshot currently available from a controlled setting comes from the Phase 2 trial published in the New England Journal of Medicine in 2023 (Jastreboff et al.; NCT04881760). That 48-week, randomized, double-blind, placebo-controlled study tested once-weekly subcutaneous doses of 1mg, 4mg, 8mg, and 12mg in 338 adults with obesity. At the highest dose of 12mg, participants achieved a mean weight loss of 24.2% at 48 weeks, compared to approximately 2.1% in the placebo group. Nearly half — 48% — of those in the 12mg group lost 25% or more of their body weight. The 8mg dose arm showed equally striking outcomes, with 70% of participants in one subgroup losing at least 20% of their body weight by week 48.
Then came TRIUMPH-4. This Phase 3 trial extended treatment to 68 weeks and delivered the most impressive mean weight loss ever recorded in a Phase 3 obesity clinical trial: 28.7% at the 12mg dose. When expressed in absolute terms over the full 80-week observation window reported in the announcement, that translated to an average loss of nearly 56 pounds. Peer-reviewed publication of the TRIUMPH-4 data is still pending as of April 2026, and no NDA has been filed with the FDA yet — but Eli Lilly's stated intention to pursue approval has generated significant anticipation among patients and clinicians alike.
To put these results in context, the table below compares retatrutide's Phase 3 findings with the leading currently approved agents:
| Medication | Mechanism | Trial | Duration | Mean Weight Loss (Highest Dose) |
|---|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 agonist | STEP-1 | 68 weeks | ~14.9% |
| Tirzepatide (Zepbound) | GLP-1 / GIP dual agonist | SURMOUNT-1 | 72 weeks | ~20.9% |
| Retatrutide (LY3437943) | GLP-1 / GIP / Glucagon triple agonist | TRIUMPH-4 (Phase 3) | 68 weeks | ~28.7% |
Beyond the scale, the Phase 2 data also documented meaningful improvements in cardiometabolic markers. At 24 weeks, the 12mg group saw fasting triglycerides fall by 34.0% and total cholesterol by 17.3%, while LDL cholesterol declined by as much as 16.9% in the 8mg group. Quality of life scores, measured by the SF-36v2, also improved across all active dose groups at week 48 — suggesting that the benefits extend well beyond the number on the scale.
Weight loss with reta begins well before the 48- or 68-week endpoint. In the Phase 2 trial, participants at the 8mg dose had already lost an average of 16.7–17.9% of their body weight by week 24 — roughly the halfway point of the study. Even at 24 weeks, 100% of participants in the 8mg group had achieved at least a 5% reduction in body weight, and 83–94% had crossed the 10% threshold.
The titration schedule plays an important role in this early trajectory. In TRIUMPH-4, the dose escalation protocol moved participants from 2mg (weeks 1–4) through 4mg, 6mg, and 9mg before reaching the 12mg maintenance dose at week 17. This gradual escalation is designed to minimize gastrointestinal side effects — primarily nausea, diarrhea, and vomiting — which are the most common adverse events and tend to peak during the titration phase. Most patients who tolerate the titration process report that food noise — the persistent, intrusive mental preoccupation with food — diminishes substantially within the first few weeks of treatment.
Safety data deserve transparent discussion. In TRIUMPH-4, discontinuation rates at the 12mg dose were 18.2%, compared to 4.0% in the placebo group — a meaningful difference, with some discontinuations attributed to perceived excessive weight loss. Dysesthesia (abnormal skin sensations) occurred in 20.9% of the 12mg group versus 0.7% of placebo participants, a rate consistent with early signals seen in the Phase 2 data. These are not minor considerations, and any patient pursuing retatrutide will benefit from discussing these risks carefully with their own physician.
The Phase 2 trial enrolled adults with a BMI of 30 kg/m² or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as hypertension or dyslipidemia. Participants with type 2 diabetes were excluded. All participants received diet and physical activity counseling as a background intervention throughout the study.
Subgroup analyses from the Phase 2 supplementary data found that weight loss outcomes were consistent across BMI categories (below and above 35 kg/m²) and across both male and female subgroups — suggesting that the efficacy signal is not limited to any particular patient profile within the eligible range. The TRIUMPH-4 population, while not yet fully described in a peer-reviewed publication, is expected to mirror a similarly broad adult obesity cohort.
Eli Lilly has announced its intention to file a New Drug Application (NDA) with the FDA on the basis of the TRIUMPH-4 results. As of April 2026, that filing has not yet been submitted, and the FDA's review timeline has not been publicly confirmed. Standard FDA review periods for priority-designated medications typically run six to twelve months from the date of filing acceptance, though timelines can vary. A peer-reviewed publication of the TRIUMPH-4 Phase 3 data is also still pending, which will provide the scientific community with the full dataset needed for independent evaluation.
Patients following this space closely should be aware that approval is not guaranteed, and that commercialization, pricing, and access decisions will unfold over time following any potential approval. The landscape, however, is moving quickly — and preparation is worthwhile.
For patients who want to stay ahead of that curve, glp3md.com maintains a waitlist for retatrutide — designed to keep prospective patients informed as the regulatory and clinical picture develops. Joining the waitlist at glp3md.com provides access to timely updates on trial results, FDA milestones, and prescribing availability as they emerge. Please note: joining the waitlist does not guarantee access to retatrutide, a prescription, or any form of treatment. Retatrutide is not FDA-approved, and no promises are made regarding medication availability. It is simply the best way to stay informed — so that when the moment arrives, the decision can be made with full knowledge and without delay.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.